Contura’s Aquamid Wrinkle Filler Hits Regulatory Bump

The FDA pushed back a public hearing for Contura Inc.'s Aquamid dermal filler so that it “can review and consider additional information that was submitted.” Aquamid was set for pre-market approval review before the watchdog agency’s General and Plastic Surgery Devices panel on Dec. 1. A new hearing date has yet to be announced. Aquamid is a permanent, “soft volume” injection designed to fill the voids underneath the surface of the skin that cause facial wrinkles. It’s biocompatible and non-allergenic; Soeborg, Denmark-based Contura claims that “its high water content makes the treated area look and feel incredibly soft and natural,” according to its website.

MORE ON THIS TOPIC